Search PubMed⌕ Search

Biomedical subjects

G Lodi

Publications and source records attributed to G Lodi.

At least 55 records · Page 3Linked to original sources

[Clinico-radiologic aspects of calcium pyrophosphate dihydrate deposition disease].

Calcium pyrophosphate dihydrate crystal deposition disease is a clinical condition characterised by Gout-like synovitis (pseudogout), calcification on and around the joints and an arthropathy that is radiologically similar to osteoarthritis (chronic pyrophosphate arthropathy). Though all these radiological clinical aspects may coexist in the same patient this is often not the case. An examination of the X-ray data on the 68 cases studied which were diagnosed on the basis of the criteria proposed by McCarty, shows that the disease is relatively common especially in the over-fifties. When chronic pyrophosphate arthropathy is the only clinical manifestation of the disease differential diagnosis from the osteoarthrosis so common in the elderly is difficult and depends on the greater severity and progression of the joint damage that may often affect joints not subjected to weight such as the shoulder, unlike what happens in osteoarthritis.

Aged↗

Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis.

The pharmacokinetics and clinical efficacy of ceftazidime, a cephalosporin with activity against Pseudomonas aeruginosa, were studied in children with cystic fibrosis. Ceftazidime had high in vitro activity against P. aeruginosa strains isolated from our patients, with a mean MIC90 of 8 micrograms/ml. The first dose of 50 mg/kg IV of ceftazidime achieved serum concentrations of 40.8 +/- 19.7 micrograms/ml at one hour and 3.8 +/- 1 micrograms/ml at four hours after administration (mean values +/- SD). The MIC90 was exceeded by serum concentrations for up to three hours. The elimination of the drug from the blood followed a biexponential decay with an elimination half-life of 60.4 +/- 6.8 min and a total body clearance of 6.0 +/- 3.1 ml/min/kg. Renal clearance of the drug accounted for 75% of the total clearance; these are higher values than those reported for adults. Peak concentrations of ceftazidime in the sputum two hours after a single administration were 4.13 +/- 2.06 micrograms/ml; after seven and 14 days of treatment, sputum concentrations were significantly lower. Eleven children with acute pulmonary exacerbation were treated for 14 days with ceftazidime at a dose of 150 mg/kg/day (12 treatment courses). Significant clinical and radiologic improvements were obtained in nine of 12 patients. In six of 11 cases the P. aeruginosa count decreased by 10(4) CFU/ml. Ceftazidime was well tolerated, and no side effects appeared during treatment.

Acute Disease↗

A specific alkaline phosphatase of amphibia integument levamisole effect on short circuit current (SCC).

Using the Ussing chamber technique we have measured the short-circuit current (SCC), and so the ion transport, in the ventral skin of samples of Rana esculenta complex. The animals were not exposed to experimental treatment, and on SCC we have observed the effect of levamisole, administered either on external or internal side. Levamisole 0.0025 mM was ineffective; higher concentrations (0.025 mM, 2.5 mM), which inhibit alPase activity in tissue extracts and sections, induced an increase in SCC measurements and the effect was proportional to the concentration. Levamisole 25 mM produced a rapid and transitory increase of SCC, followed by a very quick decrement of it. Because of the action of Levamisole, "specific inhibitor of alPase activity", on ion transport in Rana skin, we propose that the alPase enzyme is probably involved in ion cutaneous transport and thus in the adaptative osmoregulation in the integument of amphibia.

Alkaline Phosphatase↗